What effects on HF hospitalization has empagliflozin shown to have in a trial of patients with diabetes and cardiovascular risk?
In a trial of patients with diabetes and cardiovascular risk, empagliflozin, an inhibitor of sodium glucose cotransporter 2, when added to standard care, was shown to reduce cardiovascular death, all-cause mortality, and HF hospitalizations. Hospitalization for HF was reduced by 35%; 10% of the patients had pre-existing HF. Consistent effects of empagliflozin were observed across subgroups defined by baseline characteristics, including patients with versus without HF.